HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

detox adjuvant

oil droplet emulsion containing Mycobacterium phlei cell wall cytoskeleton and monophosphoryl lipid A from Salmonella minnesota R595

Networked: 7 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Related Diseases

1.	Ovarian Neoplasms (Ovarian Cancer) 05/01/1992 - "Nine of the ten ovarian cancer patients showed a significant increase in IgM titer above pre-existing levels following immunizations with TF alpha-KLH plus DETOX adjuvant. " 05/01/1992 - "In a phase I study, ten ovarian cancer patients with extensive metastatic disease despite chemotherapy were immunized three to eight times subcutaneously with the synthetic form of the immunodominant disaccharide (beta Gal1----3 alpha GalNAc) of the Thomsen-Friedenreich antigen conjugated to KLH (TF alpha-KLH) plus DETOX adjuvant. " 06/01/1996 - "Patients with metastatic breast, colorectal or ovarian cancers received active specific immunotherapy (ASI) with Theratope sialyl-Tn-KLH (keyhole limpet hemocyanin) cancer vaccine emulsified in Detox adjuvant. " 05/16/1995 - "Lymphocyte activation markers CD69 and HLA-DR were studied in metastatic breast and ovarian cancer patients who received active specific immunotherapy (ASI) using cancer vaccines containing the synthetic tumor-associated antigen sialyl-Tn or the Thomsen-Friedenreich antigen conjugated to KLH plus DETOX adjuvant. "
2.	Breast Neoplasms (Breast Cancer) 08/12/1993 - "Immune responses of mice and human breast cancer patients following immunization with synthetic sialyl-Tn conjugated to KLH plus detox adjuvant." 01/01/1993 - "Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant." 06/10/1998 - "Sixteen metastatic breast cancer patients were immunized with a low dose (5 micrograms) of a 16 amino acid MUC1 peptide (GVTSAPDTRPAPGSTA) conjugated to KLH (BP16-KLH) plus DETOX adjuvant and evaluated for antibody titers against MUC1 peptide and KLH and for cytotoxic lymphocyte (CTL) activity using class 1 HLA-matched MUC1-positive tumor targets. " 01/01/1993 - "In this first pilot study of synthetic sialyl-Tn hapten conjugated to keyhole limpet hemocyanin (STn-KLH), with Detox adjuvant, toxicity and humoral immunogenicity were assessed in 12 patients with metastatic breast cancer. "
3.	Neoplasms (Cancer) 06/10/1998 - "Sixteen metastatic breast cancer patients were immunized with a low dose (5 micrograms) of a 16 amino acid MUC1 peptide (GVTSAPDTRPAPGSTA) conjugated to KLH (BP16-KLH) plus DETOX adjuvant and evaluated for antibody titers against MUC1 peptide and KLH and for cytotoxic lymphocyte (CTL) activity using class 1 HLA-matched MUC1-positive tumor targets. " 05/16/1995 - "Lymphocyte activation markers CD69 and HLA-DR were studied in metastatic breast and ovarian cancer patients who received active specific immunotherapy (ASI) using cancer vaccines containing the synthetic tumor-associated antigen sialyl-Tn or the Thomsen-Friedenreich antigen conjugated to KLH plus DETOX adjuvant. "
4.	Colorectal Neoplasms (Colorectal Cancer) 01/01/1996 - "The humoral immune response of 85 metastatic breast, ovarian, and colorectal cancer patients was analyzed after immunization with THERATOPE STn-KLH (KLH, keyhole limpet hemocyanin) cancer vaccine emulsified in DETOX adjuvant. "

Related Drugs and Biologics

1.	Thomsen-Friedenreich antigen
2.	Disaccharides
3.	Cancer Vaccines
4.	sialyl-Tn antigen-keyhole-limpet hemocyanin conjugate
5.	keyhole-limpet hemocyanin (keyhole limpet hemocyanin)
6.	Peptides (Polypeptides)
7.	Immunoglobulin M (IgM)
8.	HLA-DR Antigens (HLA-DR)
9.	Haptens
10.	Glycoconjugates

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Immunotherapy